<DOC>
	<DOCNO>NCT00000633</DOCNO>
	<brief_summary>To determine safety immunogenicity vaccinia-derived HIV-1 recombinant envelope glycoprotein ( gp160 ) asymptomatic HIV-infected adult volunteer . To compare safety immunogenicity two different schedule gp160 administration . To examine effect gp160 hepatitis B vaccine ( Engerix-B ) various marker viral load select immune parameter . Potentiation patient 's immune response HIV might possibly prolong period clinical latency protect patient indefinitely . Preliminary result study Immuno-AG recombinant gp160 vaccine healthy volunteer infect HIV suggest vaccine safe produce antibody virus . Because another previous study fail demonstrate specific anti-HIV response patient inject recombinant vaccinia virus contain HIV-1 gene , study also test immunotherapeutic role immunization ( hepatitis B vaccination ) would expect induce nonspecific immune response HIV-infected person .</brief_summary>
	<brief_title>A Phase I Multicenter Clinical Trial Evaluate Safety Immunogenicity Immuno-AG Recombinant HIV gp160 Asymptomatic HIV Seropositive Individuals</brief_title>
	<detailed_description>Potentiation patient 's immune response HIV might possibly prolong period clinical latency protect patient indefinitely . Preliminary result study Immuno-AG recombinant gp160 vaccine healthy volunteer infect HIV suggest vaccine safe produce antibody virus . Because another previous study fail demonstrate specific anti-HIV response patient inject recombinant vaccinia virus contain HIV-1 gene , study also test immunotherapeutic role immunization ( hepatitis B vaccination ) would expect induce nonspecific immune response HIV-infected person . Fifty-five healthy HIV-positive volunteer randomly assign one follow treatment arm : six injection ( arm I ) four injection ( arm II ) HIV-1 gp160 vaccine , four injection hepatitis B vaccine non-HIV viral vaccine control ( arm III ) , six placebo injection consist adjuvant vehicle use gp160 vaccine ( arm IV ) . Immunizations placebo give 4-week interval 5 month . To maintain blinding , adjuvant vehicle placebo administer day 84 112 volunteer receive four instead six vaccine injection ( arm II III ) . Volunteers follow 4-month interval 2 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : Prophylaxis isoniazid patient previously treat . Patients must : HIV seropositivity Western blot . Normal history physical exam ( generalize lymphadenopathy acceptable ) . Mean CD4 cell count = &gt; 600 cells/mm3 visit ( minimum 2 count ) within 60 day prior study entry , single count &lt; 450 cells/mm3 . Negative PPD test normal chest xray positive PPD ( induration = &gt; 5 mm ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Hepatitis B surface antigen positive . Evidence AIDS ARCdefining opportunistic infection . Evidence disseminate tuberculosis , severe persistent candidiasis , oral hairy leukoplakia , prolong severe diarrhea , herpes zoster , herpes simplex persist one month . Active syphilis . Patients follow prior condition exclude : Evidence psychiatric disorder within past year would impair adherence protocol . History AIDS ARCdefining opportunistic infection . History disseminate tuberculosis , severe persistent candidiasis , oral hairy leukoplakia , prolong severe diarrhea , herpes zoster , herpes simplex persist one month . Prior Medication : Excluded : Immunomodulating agent ( e.g. , isoprinosine , imuthiol , lithium ) within 90 day screen . Immunosuppressive medication within previous 3 month . Zidovudine ( AZT ) antiviral agent ( include interferon ) within previous 6 month . Vaccination pathogen within 4 week initial screen laboratory work . Use illicit drug significant amount alcohol could significantly interfere study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>